NIH R01 · 2024
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus
PROJECT SUMMARY/ABSTRACT Herpes zoster (HZ, or shingles) is a major cause of morbidity, affecting one in three Americans during their lifetime. HZ can be particularly devastating when it involves the eye (herpes zoster ophthalmicus, HZO) and can result in permanent vision loss. The FDA approved a highly effective HZ vaccine (Shingrix, recombinant zoster vaccine [RZV]) in late 2017 for ages 50 and above. Our group published the first post-licensure observational studies of real-world effectiveness of RZV using two years of data. Long-term monitoring of RZV uptake, effectiveness and safety, as well as its impact on HZ/HZO incidence is critical to guide vaccination efforts. During our current…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.